NCT03955640 2025-12-22Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall RecurrencesThomas Jefferson UniversityPhase 1 Terminated3 enrolled
NCT06065059 2024-08-13Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsTango Therapeutics, Inc.Phase 1/2 Terminated7 enrolled
NCT04586335 2024-03-21Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.Haihe Biopharma Co., Ltd.Phase 1 Terminated24 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02561832 2019-02-20A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerAstraZenecaPhase 1 Terminated15 enrolled 8 charts